Is KPV approved or legal?

KPV is not an approved drug and is not authorized for human therapeutic use by major regulators. It is sold and discussed as a research compound only. Legality of possession varies by jurisdiction; it is not a validated medical treatment.

What is KPV's half-life and how often is it dosed?

As a small tripeptide, KPV's serum half-life is short (estimates around 25-35 minutes). Anecdotal community protocols therefore use once- or twice-daily dosing, but no human dosing has been clinically established.

What does KPV actually do?

In cell and animal studies it acts as an anti-inflammatory, suppressing NF-kappaB and MAP-kinase signaling and reducing inflammatory cytokines, with the best data in rodent colitis models. Human efficacy has not been demonstrated in controlled trials.

Research and community use spans subcutaneous injection (systemic), oral forms (gut-targeted), and topical creams (skin). Route choice reflects the target tissue; none of these has validated human dosing.

Preclinical studies show good tolerability with no documented organ toxicity at tested doses, but there is no long-term human safety data. Reported issues are mild and mostly injection-site reactions. Consult a qualified clinician before any use.

Recovery

KPV

Also known as: Lysine-Proline-Valine, Lys-Pro-Val, alpha-MSH(11-13), Alpha-MSH C-terminal tripeptide

Anti-inflammatory tripeptide from alpha-MSH; promising preclinical gut/skin data, no human efficacy trials. Research use only.

Last updated July 11, 2026

Reconstitute this peptide Buy KPV

Overview

KPV (lysine-proline-valine) is a tripeptide corresponding to the C-terminal sequence (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike the full alpha-MSH molecule, KPV does not appear to activate classical melanocortin receptors or raise intracellular cAMP, yet it retains anti-inflammatory activity, making it a focus of research into receptor-independent immune modulation. Most of the evidence for KPV comes from preclinical work: cell-culture experiments and rodent models of inflammatory bowel disease (colitis), contact dermatitis, and systemic inflammation. It is studied across multiple routes (oral, topical, and subcutaneous) because different formulations target different tissues - the gut, the skin, or systemic inflammation. It is important to be clear about the evidence ceiling: there are no published controlled human efficacy trials demonstrating clinical benefit, and no regulatory approval of KPV as a drug. Marketed dosing protocols are derived from animal studies and community/vendor anecdote, not from human trials. KPV is sold and discussed strictly as a research compound, not as a treatment for any condition.

How it works

KPV is taken up into intestinal epithelial and immune cells, in part via the di/tripeptide transporter PepT1, and acts intracellularly rather than through melanocortin-receptor signaling. In preclinical models it suppresses pro-inflammatory NF-kappaB signaling (reducing IKK activity and preserving IkappaB-alpha, which limits NF-kappaB nuclear translocation) and dampens MAP-kinase pathways, lowering secretion of pro-inflammatory cytokines. Reported downstream effects include reduced inflammatory cytokine expression and decreased tissue inflammation in colitis models. These mechanisms are established in vitro and in animals; their relevance and magnitude in humans have not been confirmed in clinical trials.

Researched effects

Preclinical Reduces intestinal inflammation and colitis severity in rodent IBD models (DSS- and TNBS-induced colitis)
Preclinical Inhibits NF-kappaB and MAP-kinase inflammatory signaling and lowers pro-inflammatory cytokine secretion in cell culture
Preclinical Reduces inflammation in models of contact dermatitis and systemic inflammation
Anecdotal May support skin conditions (acne, eczema, psoriasis) and wound healing when applied topically
Anecdotal Reported subjective gut-symptom relief and reduced inflammation with oral or injectable use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans. Published evidence is limited to in-vitro and rodent studies (e.g., nanomolar concentrations in cell culture; oral and parenteral dosing in mouse colitis models). No human dose-finding or efficacy trials have defined a safe or effective clinical dose.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice. Community guides and vendor educational pages (e.g., peptides.org, peptidedosages.com) and forum/Reddit-style discussion commonly cite: subcutaneous ~200-500 mcg once daily for systemic anti-inflammatory experimentation; oral capsules/sprays for gut-targeted use (figures range widely and inconsistently across sources, from microgram to milligram amounts, reflecting the lack of standardization); and topical creams/serums at roughly 0.1-1% (or a few mg per application) for skin. Cycle lengths reported anecdotally are typically short (a few weeks). These figures are unverified, conflict between sources, and should be treated as research reference points, not dosing instructions.

Half-life: Short - reported on the order of ~25-35 minutes in serum for the intact tripeptide (estimates; not firmly established in humans)
Routes: subcutaneous, oral, topical

Safety & side effects

KPV is generally described as well tolerated in preclinical work, with no documented organ toxicity or dose-limiting events in rodent studies at the doses tested. However, long-term and controlled human safety data do not exist. Anecdotally and in analogous peptide use, the most commonly reported issues are mild injection-site reactions (redness, swelling, transient induration), occasional mild nausea, and rare hypersensitivity. Sourcing is a real-world risk: research-grade material can vary in purity and sterility. KPV is not an approved drug and has not been validated for human therapeutic use; anyone considering it should consult a qualified clinician.

Research summary

The strongest evidence for KPV is preclinical and centers on inflammation, particularly in the gut. A landmark 2008 Gastroenterology study (Dalmasso et al.) showed that PepT1-mediated uptake of KPV reduces intestinal inflammation in two mouse colitis models, and a companion 2008 paper in Inflammatory Bowel Diseases (Kannengiesser et al.) reported anti-inflammatory potential of the melanocortin-derived tripeptide in murine IBD. Mechanistic work attributes these effects to intracellular suppression of NF-kappaB and MAP-kinase signaling and reduced cytokine output, independent of melanocortin receptor activation. Later work has explored targeted oral delivery (e.g., hyaluronic-acid-functionalized nanoparticles) to improve colonic delivery in colitis models. Despite a coherent and reproducible preclinical picture, the translational gap is large. There are no published controlled human trials demonstrating efficacy for IBD, skin disease, or general 'recovery,' and KPV has no regulatory approval as a therapeutic. The multi-route popularity (oral, topical, subcutaneous) seen in the consumer/research-peptide market is driven by mechanism plausibility and anecdote rather than human outcome data. On balance, KPV is a mechanistically interesting anti-inflammatory tripeptide with genuine preclinical support but unproven human benefit and limited human safety data. Claims of clinical benefit should be treated cautiously and graded as preliminary. It is appropriate to frame KPV as a research compound, not a validated treatment.

FAQ

Is KPV approved or legal?: KPV is not an approved drug and is not authorized for human therapeutic use by major regulators. It is sold and discussed as a research compound only. Legality of possession varies by jurisdiction; it is not a validated medical treatment.
What is KPV's half-life and how often is it dosed?: As a small tripeptide, KPV's serum half-life is short (estimates around 25-35 minutes). Anecdotal community protocols therefore use once- or twice-daily dosing, but no human dosing has been clinically established.
What does KPV actually do?: In cell and animal studies it acts as an anti-inflammatory, suppressing NF-kappaB and MAP-kinase signaling and reducing inflammatory cytokines, with the best data in rodent colitis models. Human efficacy has not been demonstrated in controlled trials.
How is KPV taken?: Research and community use spans subcutaneous injection (systemic), oral forms (gut-targeted), and topical creams (skin). Route choice reflects the target tissue; none of these has validated human dosing.
Is KPV safe?: Preclinical studies show good tolerability with no documented organ toxicity at tested doses, but there is no long-term human safety data. Reported issues are mild and mostly injection-site reactions. Consult a qualified clinician before any use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.